IHC 2017

Cardiovascular Study Supports Safety of Novel Migraine Tx Erenumab

By September 11, 2017

Results showed that at the end of the 12-week trial participants in the Aimovig 140mg group had a reduction of 7 MMDs and the 70mg group had a reduction of 5.4 days, while the placebo group had a reduction of 2.7 days (P<0.001).